Wegovy and Zepbound costs capped at $200 in new Evernorth programme
Evernorth, the pharmacy benefits unit for health insurer giant Cigna, has reached a deal with drugmakers Novo Nordisk and Eli …
Post
-
-
Lilly’s Kisunla marketing for Alzheimer’s authorised in Australia
Eli Lilly and Company has received marketing authorisation from the Australian Therapeutic Goods Administration (TGA) for Kisunla (donanemab) to treat …
-
UK biopharma innovator venture financing surges to $1.1bn in Q1 2025
UK biopharmaceutical companies saw a surge in venture financing for innovator drugs in 2024, with double the total deal value …
-
Overcoming cold-chain logistical challenges when delivering life-saving MS therapies
With the MS Trust estimating that more than 2.9 million people worldwide have multiple sclerosis (MS), new therapies are urgently …
-
Orionis and Genentech link on oncology small-molecule glue medicines
Orionis Biosciences has announced a multi-year partnership with Roche’s Genentech, focusing on the discovery and development of small-molecule monovalent glue …
-
Moderna shares down after pulling Covid-flu combo vaccine application
Moderna has “voluntarily” withdrawn its application to the US Food and Drug Administration (FDA) for approval of its Covid-19 and …
-
Can pharma tariffs “Make America Manufacture Again”?
As President Trump continues to signal import tariffs on pharmaceuticals to bolster US manufacturing, experts warn this could hike costs …
-
Viz.ai, Sanofi and Regeneron to link for COPD management
Viz.ai is to enter a multi-year collaboration with Sanofi and Regeneron aimed at deploying and assessing an AI-powered workflow solution …
-
Navigating new EU regulations in the clinical supply chain
The latest EU clinical trial regulations must be carefully understood. The Clinical Trial Regulation (CTR) was introduced in the EU …
-
ATS 2025: Real-world cohort study aligns with GSK depemokimab narrative
On 20 May at the American Thoracic Society (ATS) 2025 conference in San Francisco, investigators from the Analysis Group, a …
-
WHO secures 20% funding increase amid US shortfall
Member countries of the World Health Organization (WHO) will pay 20% more in membership fees as part of a revamped …
-
ATS 2025: GSK strengthens argument for twice-annual depemokimab
On 20 May 2025 at the American Thoracic Society (ATS) International Conference in San Francisco, a poster presentation by GlaxoSmithKline …
-
BioNTech to invest up to $1.34bn in UK R&D
BioNTech has made a grant agreement with the UK government to expand its research and development (R&D) activities for medicines, …
-
FDA to restrict Covid-19 booster doses to older adults
The US Food and Drug Administration (FDA) is set to restrict Covid-19 booster doses to older adults and those at …
-
HHS sets “most favoured nation” pricing targets for drug makers
The US Department of Health and Human Services (HHS) said it is “taking immediate steps” to implement a recent Executive …
